草分枝杆菌治疗结核性渗出性胸膜炎68例临床疗效观察(1)
 |
| 第1页 |
参见附件(2517KB，2页)。
【摘要】目的 观察草分枝杆菌注射液(乌体林斯)治疗结核性渗出性胸膜炎疗效及对远期疗效的影响。方法 结核性渗出性胸膜炎68例，随机分成乌体林斯治疗组及激素对照组，观察在全身化疗的基础上，乌体林斯治疗后的疗效。结果 结核性渗出性胸膜炎经乌体林斯治疗后疗程缩短至9个月，随访二年无复发，近期疗效、远期疗效明显高于对照组。结论 草分枝杆菌注射液治疗结核性渗出性胸膜炎疗效肯定。
【关键词】结核性渗出性胸膜炎 肺/药物疗法 草分枝杆菌菌注射液
中图分类号：R521.7 文献标识码：B 文章编号：1005-0515(2011)7-255-02
Clinical analysis of mycobacteriumphlei immunotherapy
in treating sixty-eight patients with Tuberculous exudative pleurisy
Zhang Honglan Li Zhiyong Li pengpeng，et al.
(Yandu Center for Disease Control and Prevention，Jiangsu ，Yancheng 224002)
【Abstract】Objective To investigate the mycobacteriumphlei (Utilin’s)immunotherapy on the duration and the long-term clinical outcomes of patients with pleural effusion due to Tuberculous exudative pleurisy (TEP). Methods sixty-eight patients with tuberculous pleural effusion were randomly divided into for either mycobacteriumphlei treatment or hormone treatment (control), respectively. The course of treatment and the long-term systemic effectiveness of the two therapies were determined and compared. Results The average period of chemotherapy were significantly reduced to 9 month in the group of mycobacteriumphlei immunotherapy; Two-year follow-up after mycobacteriumphlei immunotherapy showed zero TEP recurrence; Both short-term and long-term clinical outcomes were significantly improved with mycobacteriumphlei therapy in comparison with those under hormone therapy. Conclusion Compared to hormone therapy, mycobacteriumphlei has a greater efficacy in treatingTEP.
【Key words】Tuberculous exudative pleurisy；pulmonary/drug therapy；mycobacteriumphlei immunotherapy
结核性渗出性胸膜炎常引起胸腔积液，是临床上最常见的胸腔积液，约占全部胸腔积液的半数，若不治疗任其发展，大约60-70%的病人可发展为活动性结核病，故及时规范治疗十分重要。草分支杆菌注射液是灭活的草分支杆菌(Myc obac terium pheli)制剂，商品名为乌体林斯(Utilin’s)，是无色、白色透明液或微混悬液，它与结核杆菌在分类上有着密切的关系，可以增强机体的细胞免疫和体液免疫功能，加快对结核菌的吞噬，促进病变消散和空洞闭合，同时能改善结核中毒症状；我们对2006-2009年期间68例结核性渗出性胸膜炎患者,在化疗的基础上应用乌体林斯(德国Sanum-Kehlbeck公司生产原料，中德合资成都金星健康药业有限公司分装)方案及激素方案进行了疗效观察,现报告如下：
1 资料与方法
1.1 一般资料
病例选择标准：(1)经临床确诊为结核性渗出性胸膜炎(临床表现、X线检查、胸水常规化验、胸膜活检、PPD试验等)且发病在2周内经各卫生院转诊至本中心治疗者。(2)无严重心、肝、肾疾患及矽肺、糖尿病。(3)无免疫变态反应性疾病。经以上标准随机抽取68例，男性47例，女性21例。其中合并肺结核的有43例，单纯性胸膜炎25例，按性别、年龄、病变部位、胸液量等随机分成治疗组34例：化疗+抽液+乌体林斯；对照组34例：化疗+抽液+激素。
1 ......
您现在查看是摘要介绍页，详见PDF附件(2517KB，2页)。